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A 75-year-old Caucasian woman was transferred to a tertiary academic medical center for 
management of a foul smelling, non-draining, unstageable sacral pressure ulcer. Upon 
admission, the patient’s laboratory data was notable for a white blood cell count (WBC) of 14.90 
x 10
-3
/µL and absolute neutrophil count of 12.24 x 10
-3 
/µL. After a complicated hospital course 
the patient was initiated on daptomycin 6 mg/kg (300 mg) daily in response to wound cultures 
detecting Enterococcus faecium susceptible only to daptomycin and linezolid. Starting 96 hours 
after daptomycin initiation, there was a profound reduction in the patient’s WBC, reaching a 
nadir of 1.63 x 10
-3 
/µL after 12 days of therapy. Prior to documented resolution of her blood 
dyscrasia the patient was transferred to hospice care and use of antimicrobial therapy was 
withdrawn. The Naranjo Adverse Drug Reaction Probability Score demonstrated a probable 
relationship (score equal to 6) between daptomycin and the development of neutropenia. Unlike 
previous reports of daptomycin-induced neutropenia and/or thrombocytopenia, where patients 
received prolonged courses of daptomycin with doses ranging from 6-10 mg/kg, this case 
describes a much more rapid onset of neutropenia that occurred at a dose of 6 mg/kg/day. This 
case reports highlights the risk for daptomycin to induce neutropenia in patients receiving 
traditional dosing, not just at higher doses, and within a shorter time-frame than previously 
documented. Healthcare providers should be cognizant of this adverse reaction, and diligent in 
monitoring for adverse events, associated with daptomycin use even when used for short courses 
or at traditional doses.  
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Introduction 
 
Neutropenia is defined as an overall reduction in the amount of neutrophils circulating within the 
body
1
. The use of an absolute neutrophil count (ANC) is used to classify the level of neutropenia 
present, with the lower level set at 1500 x 10
-3 
/µL
1
.
 
Mild neutropenia is defined by an ANC 
between 1000-1500 x 10
-3 
/µL, moderate neutropenia and severe neutropenia are defined by 
ANCs of 500-1000 x 10
-3 
/µL and <500 x 10
-3 
/µL, respectively
1
.
 
Initial symptoms of neutropenia 
often include new-onset infections coupled with fevers and malaise
1
. When patients develop 
neutropenia secondary to antibiotic use, such infections can be difficult to differentiate from a 
primary infection.  
    The use of daptomycin, a cyclic lipopeptide antibacterial agent approved for use in the 
management of complicated skin and skin structure and Staphylococcus aureus bloodstream 
infections, has increased due to greater rates of drug-resistant gram-positive bacterial infections
2
. 
Despite being an appropriate agent for management of such drug-resistant gram-positive 
infections in neutropenic patients, several case reports describe the development of neutropenia 
or thrombocytopenia secondary to daptomycin use
3-6
. We report a case of neutropenia attributed 
to the use of daptomycin in a patient with an Enterococcus faecium pressure ulcer.  
 
Case Presentation 
 
A 75-year old Caucasian female (height, 154.2 cm, weight, 49.9 kg) was transferred to a tertiary 
academic medical center from a rehabilitation facility for the management of new onset, foul 
smelling, non-draining, unstageable sacral pressure ulcer measuring 8 centimeters x 7 cm. The 
patient’s past medical history was significant for a recent subdural hematoma, as well as a past 
cerebrovascular accident, dementia, essential hypertension, hyperlipidemia and type 2 diabetes 
mellitus. In the emergency department the patient was noted to have a maximum temperature of 
39.1°C, blood pressure of 126/68 mmHg, heart rate of 93/minute, and a respiratory rate of 20 
with normal breath sounds. Baseline admission laboratory data was notable for a serum 
creatinine of 0.4 mg/dL, calculated creatinine clearance of 112.4 mL/min via the Cockcroft-
Gault equation, white blood cell (WBC) count of 14.90 x 10
-3 
/µL (baseline 8.3 x 10
-3 
/µL), ANC 
of 12.24 x 10
-3 
/µL (baseline 5.83 x 10
-3 
/µL), and a platelet count of 369 x 10
-3 
/µL. 
   While in the emergency department the patient received a computed tomography scan of her 
head, chest, abdomen and pelvis which revealed a resolving bilateral subdural hematoma and a 
large pressure ulcer of the sacrum with edema extending into the coccyx and S5 vertebra 
concerning for osteomyelitis. Empiric therapy with intravenous (IV) cefepime 1000 mg every 12 
hours and IV vancomycin 1000 mg every 12 hours was initiated after obtaining blood, stool, and 
urine cultures.  Based on hospital dosing recommendations, a vancomycin trough was obtained 
prior the third dose on hospital day 2, and returned at 9.7 µg/mL, after which the vancomycin 
dose was changed to 1250 mg every 12 hours; resulting in a trough level of 16.1 µg/mL which 
was drawn on hospital day 4. By hospital day 5 all cultures were finalized and demonstrated no 
bacterial growth. The patient continued to have intermittent elevated temperatures during this 
time period (temperature maximum of 38.4°C) but the WBC normalized to 7.96 x 10
-3 
/µL. 
Vancomycin was discontinued on hospital day 5 and the patient remained on cefepime until 
hospital day 10 when it was discontinued by the hospital medicine team as the patient had 
remained afebrile for 72 hours combined with a lack of microbial presence within the culture 
data.  
   By hospital day 13 the patient’s sacral pressure ulcer was reportedly improving, measuring 7 
cm x 6.5 cm, and the patient was being prepared for discharge to a rehabilitation facility. But on 
the evening of hospital day 13 the patient became febrile with a rectal temperature of 38.8°C, and 
laboratory data was notable for a WBC of 13.44 x 10
-3 
/µL, ANC of 7.83 x 10
-3 
/µL and non-
highly sensitive C-reactive protein (CRP) of 231.4 mg/L. Blood cultures were sent and the 
patient was re-initiated on IV cefepime (2000 mg every 12 hours due to a concern for hospital-
acquired gram-negative organisms) and IV vancomycin (1000 mg every 12 hours). Over the next 
5 days, hospital days 15-19, the patient remained on cefepime and vancomycin, was afebrile with 
the exception of two readings, both of 38.3°C, on hospital days 16 and 17, and a documented 
WBC within normal limits (range 6.88 to 10.2 x 10
-3 
/µL).  
    On hospital day 17 the patient was taken to the operating room for debridement of the pressure 
ulcer. Wound cultures grew Enterococcus faecium and Prevotella species on hospital day 20 and 
the patient’s antibiotic regimen was changed from vancomycin and cefepime to IV daptomycin 
300 mg (6 mg/kg) every 24 hours and IV ampicillin/sulbactam 3 grams every 6 hours. 
Approximately 72 hours later, on hospital day 23, the E. faecium was noted to be resistant to 
ampicillin and vancomycin, with minimum inhibitory concentration 90% (MIC90) of >8 µg/mL 
and >16 µg/mL, respectively). No further susceptibilities were reported for the Prevotella 
species. Ampicillin/sulbactam was discontinued, IV ertapenem 1000 mg every 24 hours was 
initiated and daptomycin was continued. Ertapenem was continued for a total of 5 days, until 
hospital day 29, and daptomycin was continued until hospital day 38.  
   It was noted that, 48 hours after initiation of daptomycin (hospital day 22), the patient’s WBC 
began to decline (Figure 1). The patient’s WBC and ANC on hospital day 23 were reported to be 
5.17 x 10
-3 
/µL and 0.27 x 10
-3 
/µL, respectively. Ninety-six hours after initiation of daptomycin 
(hospital day 24), the patient’s WBC underwent an approximate 45% reduction to 3.39 x 10-3 
/µL.  
 
 
 
 
Figure 1. Trend in the patient’s WBC, neutrophil and platelet counts over hospital days 13-39, with hospital days 1 
and 7 included for baseline reference.  
 
   On hospital day 31 a workup began for neutropenia, including evaluation of drug-induced 
causes. Prior to this period of time, routine evaluation of the patient’s ANC was not undertaken 
consistently. Other causes of neutropenia were ruled out via laboratory testing, including anemia, 
malignancy and vitamin deficiencies. Upon evaluation by Infectious Diseases, Hospital Medicine 
and Neurology services, neutropenia was suspected to be drug-induced. After thoroughly 
reviewing the patient’s medication history, various agents were ruled out, specifically, the use of 
ampicillin/sulbactam, vancomycin and ertapenem were felt not to be contributory because the 
timeline of their use was not consistent with the onset of neutropenia and thrombocytopenia. 
Daptomycin was the only new agent identified during the time period when neutropenia and 
thrombocytopenia developed. When estimating the likelihood that the patient’s neutropenia was 
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White blood cell, absolute neutrophil count, and  
platelet trend by hospital day 
 a result of daptomycin use, the Naranjo Adverse Drug Reaction Probability Score demonstrated a 
probable relationship (score equal to 6)
7
.
 
This score was calculated based on the presence of 
previous case reports supporting this reaction (+1), the presence of a sustained decrease in WBC 
count after initiation of daptomycin (+2), a lack of likely alternate causes (+2), and confirmation 
of the reaction was based on objective evidence (+1). When evaluating other potential 
medication-causes of this reaction, the use of alternative antibiotics did not generate a Naranjo 
score as high as that calculated for daptomycin, largely based on the lack of persistent reductions 
in WBC count and/or platelet counts during treatment.  
   The patient’s WBC and ANC reached a nadir on hospital days 32 and 33 with a value of 1.63 x 
10
-3 
/µL and 0.27 x 10
-3 
/µL, respectively. On hospital day 38 the patient requested withdrawal of 
care due to a concern for treatment futility. Subsequently, all antibiotic therapy was discontinued 
and laboratory monitoring ceased. The patient transitioned to target comfort measures only and 
she was transferred to a healthcare facility closer to her home. Confirmatory testing using 
Immunoglobulin (Ig) G antiplatelet antibodies was not done due to non-availability. 
 
Discussion 
 
Drug-induced neutropenia has been attributed to a number of pharmacologic agents, including 
antibacterial agents. Of the eleven agents accounting for greater than fifty percent of all reported 
cases of drug-induced neutropenia, the use of penicillin, trimethoprim-sulfamethoxazole and 
dapsone rank amongst the most likely agents to induce neutropenia
8,9
. The development of 
neutropenia by these agents has been proposed to include both immunologic and non-
immunologic, or cytotoxic, mechanisms. However, specifics surrounding these mechanisms are 
lacking within the literature. From the published literature surrounding the use of daptomycin, 
there have been three published case reports to date, implicating its use in the development of 
neutropenia and/or thrombocytopenia.  
   Knoll and colleagues described their findings from a 53-year-old woman diagnosed with B-cell 
non-Hodgkin lymphoma who, after 10 weeks of daptomycin therapy at 6 mg/kg/day, developed 
neutropenia
3
. At that time the patient’s WBC and ANC were reported to be 1.6 x 10-3 /µL and 0.8 
x 10
-3 
/µL, with no reported change in her platelet count. Upon discontinuation of daptomycin, 
the patient had resolution of her neutropenia with a reported WBC of 5 x 10
-3 
/µL and an ANC of 
3.4 x 10
-3 
/µL. Furthermore, Leyra and colleagues described a case of a 75-year-old woman who 
developed both neutropenia and thrombocytopenia associated with prolonged, high dose 
daptomycin (10 mg/kg/day) in the management of endocarditis
4
. This patient developed her 
blood dyscrasias on the 28
th
 day of daptomycin and cefepime therapy. After discontinuation of 
cefepime on the 35
th
 day and daptomycin on the 38
th
 day the WBC and platelet counts 
normalized, after reaching a nadir of 2.2 x 10
-3 
/µL and 0.04 x 10
-3 
/µL, respectively. After a total 
intensive care unit stay of 64 days the patient was deemed stable enough to be transferred to the 
medical floor.  
   In a separate case, Gregoire and colleagues described a 64-year-old man admitted to an 
intensive care unit who received daptomycin 6 mg/kg/day, in addition to other targeted agents, 
for an abdominal abscess positive for Staphylococcus epidermidis, Enterococcus faecalis and 
Pseudomonas aeruginosa
5
. After four days of therapy the patient developed extensive purpura 
and a reported platelet count of less than 0.01 x 10
-3 
/µL. Subsequently, the patient died 
secondary to a brain herniation. Additionally, Hartmann and colleagues described another case of 
thrombocytopenia attributed to daptomycin
6
. In this case a patient with S. epidermidis bacteremia 
 developed thrombocytopenia, with a platelet count of 5.2 x 10
-3 
/µL, after receiving 6 weeks of 
daptomycin at a dose of 6 mg/kg/three times weekly dose reduced for dialysis. Table 1 
summarizes each of the published case reports outlined above. Lastly, various mechanisms 
evaluated by the authors of the above referenced case reports have been explained in these case 
reports. Gregorie and colleagues found a high presence of megakaryocytes in a bone marrow 
aspirate of their patient, which they attributed to the breakdown of circulating platelets, as well 
as daptomycin-specific antibodies bound to platelets via flow-cytometry, indicating an immune-
mediated mechanism behind the development of thrombocytopenia. 
 
 
Table 1. Summary of published case reports on daptomycin related neutropenia and/or thrombocytopenia 
 
Reference 
number 
Patient data Rationale for 
daptomycin 
use 
Daptomycin 
dose 
Timeline of onset of 
blood dyscrasias 
after daptomycin 
initiation (days) 
Type of blood 
dyscrasias and 
severity 
Outcome 
3 53 year old 
woman with 
B-cell non-
Hodgkin 
lymphoma 
Methicillin-
resistant S. 
aureus septic 
arthritis not 
responding to 
11 weeks of 
intravenous 
vancomycin 
therapy 
6 mg/kg/day 70 Neutropenia only. 
 
Baseline: WBC / 
ANC was 5.6 x 10-
3/µL and 4.1 x 10-
3/µL 
 
Nadir: WBC / ANC 
was 1.6 x 10-3/µL 
and  
0.8 x 10-3/µL 
Resolution of 
neutropenia 7 
days after drug 
discontinuation. 
4 75 year old 
woman 
undergoing 
bio-
prosthetic 
mitral valve 
surgery 
Empiric 
management of 
new-onset 
malaise, fever 
and dyspnea 
approximately 
one month 
after surgery 
10 
mg/kg/day 
33 
(thrombocytopenia) 
41(neutropenia) 
Thrombocytopenia 
(day 33), and 
neutropenia (day 
41). 
 
Platelet count on 
day 28 was 200 x 
10-3/µL.  
 
Nadir: Platelet count  
27 x 10-3/µL, ANC  
0.07 x 10-3/µL. 
Transferred to 
the medical floor 
after 64 days in 
intensive care. 
5 64 year old 
man 
admitted to 
an 
intensive-
care unit 
Polymicrobial 
abdominal 
abscess, 
including E. 
faecalis  
6 mg/kg/day  4  Thrombocytopenia 
only. 
 
No baseline platelet 
count reported, but 
count after 4 days of 
therapy was  
<10 x 10-3/µL. 
Died  
6 61 year old 
man on 
dialysis   
S. epidermidis 
bacteremia 
6 
mg/kg/three 
times 
weekly 
42 Thrombocytopenia 
only. 
 
No baseline platelet 
count reported, but 
count after 42 days 
of therapy was  
52 x 10-3/µL. 
Antibiotic 
regimen was 
discontinued but 
5 weeks later 
patient sustained 
a cardiac arrest 
and died.  
 
 
   While there are similarities between our case and those in the published literature, there are 
distinct differences that are worth highlighting. First, our patient, like the case report by Leyra 
and colleagues developed both neutropenia and a thrombocytopenia rapidly after initiation of 
daptomycin. However, the dose of daptomycin used was lower in our patient, i.e 6 mg/kg/day 
 versus 10 mg/kg/day. Unlike the other cases, our patient developed her blood dyscrasias much 
more rapidly. 
   In conclusion, our case adds to the existing literature surrounding the development of 
neutropenia and thrombocytopenia with the use of daptomycin. Furthermore, it demonstrates that 
such blood dyscrasia can occur even at lower doses, and with shorter courses of therapy, than 
previously noted in the literature. 
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